An earlier start for HIV therapy

Nature Medicine

Volumn 15, Issue 8, 2009, Pages 848-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KIDNEY DISEASE; LIVER DISEASE; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; SENESCENCE; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS IDENTIFICATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC SURVEILLANCE; MODELS, BIOLOGICAL; T-LYMPHOCYTES; TIME FACTORS; VIRUS REPLICATION;

EID: 68349146449     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0809-848     Document Type: Note

References (3)

1. When to Start Consortium et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373, 1352-1363 (2009).
2. Kitahata, M.M. et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360, 1815-1826 (2009).
3. Pensieroso, S. et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 in vertically-infected children. Proc. Natl. Acad. Sci. USA 106, 7939-7944 (2009).